Literature DB >> 27413119

Induction of the UDP-Glucuronosyltransferase 1A1 during the Perinatal Period Can Cause Neurodevelopmental Toxicity.

Rika Hirashima1, Hirofumi Michimae1, Hiroaki Takemoto1, Aya Sasaki1, Yoshinori Kobayashi1, Tomoo Itoh1, Robert H Tukey1, Ryoichi Fujiwara2.   

Abstract

Anticonvulsants can increase the risk of developing neurotoxicity in infants; however, the underlying mechanism has not been elucidated to date. Thyroxine [3,5,3',5'-l-tetraiodothyronine (T4)] plays crucial roles in the development of the central nervous system. In this study, we hypothesized that induction of UDP-glucuronosyltransferase 1A1 (UGT1A1)-an enzyme involved in the metabolism of T4-by anticonvulsants would reduce serum T4 levels and cause neurodevelopmental toxicity. Exposure of mice to phenytoin during both the prenatal and postnatal periods significantly induced UGT1A1 and decreased serum T4 levels on postnatal day 14. In the phenytoin-treated mice, the mRNA levels of synaptophysin and synapsin I in the hippocampus were lower than those in the control mice. The thickness of the external granule cell layer was greater in phenytoin-treated mice, indicating that induction of UGT1A1 during the perinatal period caused neurodevelopmental disorders. Exposure to phenytoin during only the postnatal period also caused these neurodevelopmental disorders. A T4 replacement attenuated the increase in thickness of the external granule cell layer, indicating that the reduced T4 was specifically associated with the phenytoin-induced neurodevelopmental disorder. In addition, these neurodevelopmental disorders were also found in the carbamazepine- and pregnenolone-16-α-carbonitrile-treated mice. Our study is the first to indicate that UGT1A1 can control neurodevelopment by regulating serum T4 levels.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27413119      PMCID: PMC4998668          DOI: 10.1124/mol.116.104174

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  56 in total

1.  Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy.

Authors:  A Ornoy; E Cohen
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

2.  Glucuronidation of thyroxine in primary monolayer cultures of rat hepatocytes: in vitro induction of UDP-glucuronosyltranferases by methylcholanthrene, clofibrate, and dexamethasone alone and in combination.

Authors:  K Jemnitz; Z Veres; K Monostory; L Vereczkey
Journal:  Drug Metab Dispos       Date:  2000-01       Impact factor: 3.922

Review 3.  Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings.

Authors:  R T Zoeller; J Rovet
Journal:  J Neuroendocrinol       Date:  2004-10       Impact factor: 3.627

4.  Intellectual impairment in children exposed to polychlorinated biphenyls in utero.

Authors:  J L Jacobson; S W Jacobson
Journal:  N Engl J Med       Date:  1996-09-12       Impact factor: 91.245

5.  CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.

Authors:  Martin Wagner; Emina Halilbasic; Hanns-Ulrich Marschall; Gernot Zollner; Peter Fickert; Cord Langner; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

6.  Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

Authors:  Sumio Ohtsuki; Olaf Schaefer; Hirotaka Kawakami; Tae Inoue; Stephanie Liehner; Asami Saito; Naoki Ishiguro; Wataru Kishimoto; Eva Ludwig-Schwellinger; Thomas Ebner; Tetsuya Terasaki
Journal:  Drug Metab Dispos       Date:  2011-10-12       Impact factor: 3.922

7.  Expression of UDP-Glucuronosyltransferase 1 (UGT1) and Glucuronidation Activity toward Endogenous Substances in Humanized UGT1 Mouse Brain.

Authors:  Yuki Kutsuno; Rika Hirashima; Masaya Sakamoto; Hiroko Ushikubo; Hirofumi Michimae; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  Drug Metab Dispos       Date:  2015-05-07       Impact factor: 3.922

8.  Status epilepticus at an urban public hospital in the 1980s.

Authors:  D H Lowenstein; B K Alldredge
Journal:  Neurology       Date:  1993-03       Impact factor: 9.910

9.  A link between liver microsomal enzyme activity and thyroid hormone metabolism in man.

Authors:  E E Ohnhaus; H Studer
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

10.  Blood pressure in relation to concentrations of PCB congeners and chlorinated pesticides.

Authors:  Alexey Goncharov; Marian Pavuk; Herman R Foushee; David O Carpenter
Journal:  Environ Health Perspect       Date:  2011-03       Impact factor: 9.031

View more
  4 in total

Review 1.  Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.

Authors:  Ryoichi Fujiwara; Emiko Yoda; Robert H Tukey
Journal:  Drug Metab Pharmacokinet       Date:  2017-10-07       Impact factor: 3.614

Review 2.  Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases.

Authors:  Ryoichi Fujiwara; Tsuyoshi Yokoi; Miki Nakajima
Journal:  Front Pharmacol       Date:  2016-10-24       Impact factor: 5.810

Review 3.  Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.

Authors:  Ruben van der Galiën; Rob Ter Heine; Rick Greupink; Stein J Schalkwijk; Antonius E van Herwaarden; Angela Colbers; David M Burger
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

4.  Severe Neonatal Hyperbilirubinemia in Crigler-Najjar Syndrome Model Mice Can Be Reversed With Zinc Protoporphyrin.

Authors:  Ryoichi Fujiwara; Ryo Mitsugi; Asuka Uemura; Tomoo Itoh; Robert H Tukey
Journal:  Hepatol Commun       Date:  2017-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.